Clinical Trial Update: Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Tegaserod at 2 mg tid and 6 mg tid in diabetic patients with diabetic gastropathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Gastropathy

Drugs mentioned

• Tegaserod (tegaserod)

Snippet

Sponsor: Novartis | Conditions: Diabetic Gastropathy | Phase 2 | Status: TERMINATED